论文部分内容阅读
目的:观察复方浙贝母药物血清对人脐带间质干细胞(MSCs)增殖抑制和凋亡影响。方法:MTT法测不同剂量组复方浙贝药物血清对人脐带MSCs的抑制率;Annexin-V/PI双染经流式细胞仪(FCM)定量检测复方浙贝药物血清诱导人脐带MSCs细胞早期凋亡率。结果:①高、中、低剂量组复方浙贝药物血清对人脐带MSCs细胞增殖抑制率分别为:3.88%、-3.37%和4.38%;含阿霉素血清组为47.88%。②经FCM双荧光法检测复方浙贝不同浓度药物血清诱导人脐带MSCs细胞早期凋亡百分比不同:空白组为35.19%,低剂量组为1.63%,中剂量组为1.19%,高剂量组为1.70%。结论:复方浙贝药物血清能部分促进人脐带MSCs的增殖(中剂量组),并保护人脐带MSCs的凋亡损伤。
Objective: To observe the effects of compound Fritillaria cirrhosae serum on the proliferation and apoptosis of human umbilical cord mesenchymal stem cells (MSCs). Methods: MTT assay was used to measure the inhibitory effect of different doses of compound ZheBai drug serum on the human umbilical cord MSCs. Annexin-V / PI double staining was used to detect the early apoptosis of human umbilical cord MSCs cells by flow cytometry (FCM) Death rate. Results: ① The inhibitory rates of compound ZheBai drug serum on the proliferation of human umbilical cord MSCs were 3.88%, -3.37% and 4.38% respectively in the high, medium and low dose groups, and 47.88% in the group containing doxorubicin. ② The percentages of early apoptosis of human umbilical cord MSCs induced by serums of different concentrations were tested by FCM double fluorescence method. The percentages of apoptosis were 35.19% in the blank group, 1.63% in the low dose group, 1.19% in the middle dose group and 1.70% in the high dose group %. CONCLUSION: The serum of compound prescription Echinococcus japonica could partially promote the proliferation of human umbilical cord MSCs (middle dose group) and protect the apoptosis of human umbilical cord MSCs.